Stage 3b: Moderate reduction in GFR (30-44 mL/min/1.73 m 2) Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m 2) Stage 5: Kidney failure (GFR < 15 mL/min/1.73 m 2 or dialysis) KDIGO guidelines recommend using creatinine-based formulas for determining the estimated glomerula...
3.Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
Metabolic acidosis in stage 5 may manifest as protein-energy malnutrition, loss of lean body mass, and muscle weakness. Altered salt and water handling by the kidney in CKD can cause peripheral edema and, not uncommonly, pulmonary edema and hypertension. Anemia, which in CKD develops primarily ...
3.Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
The study included 1,418 patients who had stage 3 to 4 CKD, which means moderately to severely reduced kidney function. All patients also had high parathyroid hormone levels (hyperparathyroidism), which can contribute to weakening of the bones in CKD. The researchers identified one group of patie...
sion and stage 1 to 3 chronic kidney disease. (Grade: strongrecommendation)Recommendation 4: ACP recommends that clinicians choose statintherapy to manage elevated low-density lipoprotein in patients withstage 1 to 3 chronic kidney disease. (Grade: strong recommenda-tion, moderate-quality evidence) ...
CKD指南：PCP指南，用于CKD检测和延缓进展说明书
Background: Although left ventricular hypertrophy (LVH) is an independent predictor of mortality in patients with end stage renal disease, few have examine... E Dervisoglu,G Kozdag,N Etiler,... - 《Hippokratia》 被引量: 18发表: 2012年 Blood coagulation system in patients with chronic kidney...
(血壓控制、貧血控制、藥物控制、血糖控制、飲食控制)營養師飲食指導設計個別性飲食計劃Stage I、II: 每6個月追蹤與記錄Stage III、Stage IV: 每3個月追蹤與記錄Stage V: 每12週或每1個月追蹤與記錄每一位病患一年至少需回診2次每半年至少舉辦一次團體衛教再次評估病患生理、生化抽血數據開始透析治療或腎移植末期...
Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment Juli . Meyers, MA1 Sean D. Candrilli, PhD2 Objective: To assess rates of diagnosis and antihyperglycemic dose adjustment in patients with Birgit Kovacs, MD3 moderate to end-stage renal impairment (RI) and type ...